OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. The company’s pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and an anti-amyloid beta peptide antibody that completed Phase I clinical trials for Alzheimer’s disease. The company was incorporated in 2001 and is headquartered in Kawasaki, Japan.
Metrics to compare | 4564 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4564PeersSector | |
---|---|---|---|---|
P/E Ratio | −7.5x | −4.8x | −0.5x | |
PEG Ratio | −0.26 | −0.22 | 0.00 | |
Price / Book | 9.2x | 3.6x | 2.6x | |
Price / LTM Sales | 10.8x | 50.1x | 3.0x | |
Upside (Analyst Target) | - | 61.4% | 55.6% | |
Fair Value Upside | Unlock | 13.2% | 10.1% | Unlock |